Skip to main content
. 2023 Feb 14;24(4):3814. doi: 10.3390/ijms24043814

Figure 3.

Figure 3

The association of RAAS inhibitors use with cervical, endometrial, and ovarian cancer risks by age groups with adjusted odds ratio. Footnote: * p < 0.05, ** p < 0.001, *** p < 0.0001.